Lucy Liu
Principal at Longwood Fund
Boston, Massachusetts
Overview
Work Experience
Principal
2022 - Current
Senior Associate
2020 - 2022
Company creator + investor dedicated to helping transform innovative sciences into therapies for patients. - lead and support due diligence efforts for newco opportunities and syndicated investments. - founding head of strategy at ImmuneID. Supported and led series seed and A fundraise. - cofounder and founding VP of strategy and operations at Carbon Biosciences. Led series A fundraise. - board observer at Pulmocide.
Longwood Fund finances science-based companies that develop novel solutions for medical problems.
Board Observer
2023
Board Observer
2022
Co-Founder, Founding VP, Strategy & Operations
2021 - 2022
Carbon Biosciences is expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues and carry a larger cargo with minimal neutralizing immunity and the potential to re-dose. Founded by Longwood Fund and gene therapy pioneers, John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D., Carbon is expanding the gene therapy toolbox for the treatment of the world’s most devastating and difficult to treat diseases. For more information, please visit our website www.carbonbio.com.
Carbon Biosciences is a biotech company that engages in the novel parvovirus gene therapy.
Raised $38,000,000.00 from Cystic Fibrosis Foundation, Longwood Fund, Astellas Venture Management, Solasta Ventures, Camford Capital, Agent Capital and UTokyo Innovation Platform.
Head of Strategy
2020 - 2021
Founded in late 2020, ImmuneID is a precision immunology Company that uses its genome-wide, high-throughput platform to provide a comprehensive understanding of individual immune responses. Based on technology developed by scientific founders Stephen Elledge (Harvard), Ben Larman (Johns Hopkins), and Tomasz Kula (Harvard), ImmuneID is employing a massively parallel, multiplexed, and unbiased systems to develop therapeutics for autoimmunity, severe allergy, oncology and infectious disease. Accomplishments: - Raised $50M series A with management team: led investor outreach and due diligence efforts - Acquired incubator lab space - Worked with management team to interview + hire R&D team - Led indication prioritization and strategy prior to CSO hire
Fellow
2020 - 2020
- Leverage scientific expertise to assist in metabolism focused newco formation with 4:59, 5AM’s internal newco formation initiative. - Assist in diligence for potential investment opportunities.
5AM Ventures is a venture capital firm that aims to finance seed and early-stage life sciences companies.
Damon Runyon Postdoctoral Fellow
2017 - 2020
Project – The fat-brain axis: identifying the roles of adipokine signaling in nervous system function. - Active contributor in an ongoing multi-institutional collaborative effort among world class scientists from HMS, MIT, Stanford, and USC. Publication in review. - Secured 4 years of research funding from the Damon Runyon Cancer Research Institute ($>250K)
Ph.D Candidate in Neuroscience
2011 - 2017
My thesis work revealed that lipid metabolic perturbations in the form of lipid droplet accumulations in glial cells (astrocytes and microglia) are a major contributing factor and a harbinger for Alzheimer's disease and neurodegeneration. These findings led to two first author manuscripts in Cell and Cell Metabolism with >900 citations. Accomplishments - Genetic Society of America Larry Sandler Memorial Award - 2018 - Harold Weintraub Graduate Student Award - 2017 - McKinsey: Houston Women Leaders Forum - 2016 - Scientific reviewer for Genetics and Scientific Reports
Undergraduate Researcher
2008 - 2011
Researcher
2009 - 2009
National Science Foundation is an independent federal agency that supports research and education in the fields of science and engineering.
Undergraduate Researcher
2008 - 2008